中國新城鎮(01278.HK)附屬南京學校項目合作方轉讓持股
中國新城鎮(01278.HK)公布,公司全資附屬中國新城鎮控股、國開南京投資發展與江蘇省建一公司、項目公司「南京國英中西建設開發」有簽署合作協議。根據協議約定,四川中西將其持有的項目公司50%股權全部轉讓給江蘇省建一公司。收購完成後,江蘇省建一公司持有項目公司50%股權,而集團合計持有項目公司的股權、在項目公司中的權利及義務沒有發生變化,項目公司仍為集團的共同控制實體。項目公司主要業務是在南京市江寧區麒麟科技園進行國際化學校項目的建設及開發,該學校為覆蓋學前教育到高中的一體化民辦教育,以雙語國際化課程為主(K12雙語課程)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.